TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05125042

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Amiodarone hydrochloride tablet + acupoint catgut embedding
Description: Patients with persistent AF after undergoing catheter ablation take receive acupoint catgut embedding in Neiguan and Zusanli twice after and one month after surgery combined with amiodarone hydrochloride tablets 200mg bid, 1 month; 200mg qd,maintained to 3 months.All patients, who had no signs of recurrence three months after surgery, stopped taking medication.
Study: NCT06508567

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: High Dose Rate Brachytherapy
Description: 2 fractions of MRI-guided HDR Brachytherapy (13Gy each) delivered over 14 days (± 7 days).
Study: NCT05971056

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Care transition
Description: Cancer care is transitioned to a satellite site.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No care transition
Description: Cancer care is not transitioned to a satellite site.
Study: NCT05585385

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Backward Walking Training
Description: The subjects in this group will receive BW training program on an electric treadmill. The subject will be asked to walk, arms beside, in a backward manner on a level treadmill, zero inclination, with a warming up and cooling down period (5 minutes for each period). The subject walks at his self-selected and comfortable walking speed. A warm-up and cool-down period, in form of light jogging on a treadmill, will be done at speed of 1-2 m/sec. The total training is 30 minutes, three times a week for six consecutive weeks.
Study: NCT05125042

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amiodarone hydrochloride tablet
Description: Patients with persistent AF after undergoing catheter ablation only take amiodarone hydrochloride tablets 200mg bid, 1 month; 200mg qd,maintained to 3 months.All patients, who had no signs of recurrence three months after surgery, stopped taking medication.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amiodarone hydrochloride tablet
Description: Patients with persistent AF after undergoing catheter ablation only take amiodarone hydrochloride tablets 200mg bid, 1 month; 200mg qd,maintained to 3 months.All patients, who had no signs of recurrence three months after surgery, stopped taking medication.
Study: NCT04410653

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib 40 MG
Description: single oral dose of afatinib each day starting at a dose of 40 mg on day 1, continuously, until the development of progressive disease or unacceptable adverse events

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib 40 MG
Description: single oral dose of afatinib each day starting at a dose of 40 mg on day 1, continuously, until the development of progressive disease or unacceptable adverse events

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib 40 MG
Description: single oral dose of afatinib each day starting at a dose of 40 mg on day 1, continuously, until the development of progressive disease or unacceptable adverse events
Study: NCT05758623

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Device
Description: The experimental group was treated with magnesium containing biodegradable polymer bone repair material produced by Shenzhen Zhongke Jingcheng Medical Technology Co., Ltd. Control group application β- Tricalcium phosphate bioceramics for treatment.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Device
Description: The experimental group was treated with magnesium containing biodegradable polymer bone repair material produced by Shenzhen Zhongke Jingcheng Medical Technology Co., Ltd. Control group application β- Tricalcium phosphate bioceramics for treatment.
Study: NCT05585385

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Balance Training
Description: Subjects in this group will receive balance training on Biodex Balance System for 3 sessions/ week, over 6 weeks period. Each subject will be instructed to stand with both legs on the locked platform. The researcher advances the platform to an unstable state while instructing the subject to focus on the visual feedback screen. Arms are free at the side of the body and not grasping handrails.~After selecting the stability training program (dynamic balance training), Stability levels are changed depending on the subject's ability to maintain balance, and subjects are instructed to maintain their Center of Pressure (COP) in the smallest concentric rings (balance zones) of the Biodex Balance System monitor, named A zone.~The stability level of the platform is set at level plate stability 8 (the most stable) for the first two sessions. After that, the plate stability is decreased by one level every two sessions to increase the difficulty in training.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional treatment
Description: Patients in this group will receive the traditional physical therapy program only for 3 sessions/ week, over 6 weeks period. The traditional physical therapy program is (evertors strengthening, short foot ex, heel raise ex, and calf stretch).
Study: NCT04705298

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Prebiotic
Description: Oligofructose-enriched inulin. 4 grams daily for ≤ age 6; or 8 grams daily for \>6 years

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Maltodextrin 4 grams daily for ≤ age 6; or 8 grams daily for \>6 years
Study: NCT06527651

Intervention type: DRUG
Group type: OTHER
Intervention: Genicular blocks (dexamethazone and lidocaine)
Description: Genicular blocks were applied bilaterally by another physiatrist who was experienced in ultrasonographic (US) interventional procedures more than 5 years. Total of 6mL solution consisting of 0.5 mg/2mL dexamethazone and 4mL %1 lidocaine for three branches of genicular nerves (superomedial, superolateral and inferomedial branches) was divided into three branches for each knee. Total of 12 mL solution was applied for each patient.
Study: NCT05719285

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Single-Dose Antibiotic
Description: Allergy, prior urine culture resistance or another contraindication to first line antibiotic will result in the patient being prescribed second line antibiotic and so forth.~First line:~Arm 1: trimethoprim / sulfamethoxazole 800/160 mg once pre-procedure~Second line:~Arm 1: cefalexin 500 mg once pre-procedure~Third line:~Arm 1: nitrofurantoin 100 mg once pre-procedure~Fourth line:~Arm 1: ciprofloxacin 500 mg once pre-procedure
Study: NCT04188366

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FAMES
Description: Participants will receive three distinct and revolving components - early, continuous, and motivational contact - that incorporate motivational techniques and the Diagnostic and Statistical Manual of Mental Disorders 5TH Edition (DSM-5) Cultural Formulation Interview (CFI).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FAMES
Description: Participants will receive three distinct and revolving components - early, continuous, and motivational contact - that incorporate motivational techniques and the Diagnostic and Statistical Manual of Mental Disorders 5TH Edition (DSM-5) Cultural Formulation Interview (CFI).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment-as-Usual
Description: Participants will receive usual services and family-based treatment offered
Study: NCT05176561

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Auditory-Cognitive Training
Description: Treatment Participants will complete 8 weeks of training for 2 hours per week and participate in a 1 hour meeting with clinician. Participants with spend 1 hour auditory training use Angel Sound and one hour of auditory cognitive training using auditory portions of Posit Science. A clinical paradigm including reviewing results, providing strategies and positive feedback and strategies in the 1 hour virtual meeting of clinician and participant. Practice for next week is assigned.~Control group intervention follows the same time and procedure but the materials are non-auditory puzzles (Sudoku, Cross Word Puzzles, Spot the Difference, Ken-Ken and Word Search).

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Non-auditory Cognitive Training
Description: Participant will complete 8 weeks of training for 2 hours per week and participate in a 1 hour meeting with clinician. Control group intervention follows the same time and clinical paradigm, but the materials are non-auditory puzzles (Sudoku, Cross Word Puzzles, Spot the Difference, Ken-Ken and Word Search).
Study: NCT04422795

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: External thermomechanical device delivering cold and vibration stimuli
Description: the thermomechanical device will be placed on the digit 2 cm proximally to the injection site with the ice wings frozen and the vibration mechanism switched on, delivering vibration and cold stimuli to the area for 30 seconds before the intramatricial injection and until needle withdrawal

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: External thermomechanical device without delivering cold and vibration stimuli
Description: the thermomechanical device will be placed on the digit 2 cm proximally to the injection site with the ice wings at unfrozen and the vibration mechanism switched off, for 30 seconds before the intramatricial injection and until needle withdrawal

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ethyl chloride skin refrigerant spray
Description: Ethyl chloride skin refrigerant spray is applied to the area of injection for 3 seconds immediately before needle insertion
Study: NCT05384704

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Empower@Home
Description: The intervention is a 9-week course of internet-based cognitive behavioral therapy. During the active intervention phase, participants will receive weekly support from a trained research staff.
Study: NCT05370456

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Local application of a HA gel for the treatment of MAGRs with mCAF technique and XCM
Description: After local anaesthesia, mCAF technique with two releasing vertical incisions will be performed. XCM will be adapted on the root surfaces and positioned at the level of the cemento-enamel junction and HA gel will be applied.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Treatment of MAGRs with mCAF technique and XCM
Description: After local anaesthesia, mCAF technique with two releasing vertical incisions will be performed. XCM will be adapted on the root surfaces and positioned at the level of the cemento-enamel junction.
Study: NCT05719285

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Multi-Dose Antibiotic
Description: Allergy, prior urine culture resistance or another contraindication to first line antibiotic will result in the patient being prescribed second line antibiotic and so forth.~First line:~Arm 2: trimethoprim / sulfamethoxazole 800/160 mg once pre-procedure plus 800/160 mg every twelve hours for 6 total doses~Second line:~Arm 2: cefalexin 500 mg once pre-procedure plus 500 mg every twelve hours for 6 total doses~Third line:~Arm 2: nitrofurantoin 100 mg once pre-procedure plus 100 mg every twelve hours for 6 total doses~Fourth line:~Arm 2: ciprofloxacin 500 mg once pre-procedure plus 500 mg every twelve hours for 6 total doses
Study: NCT05678998

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WTX-330
Description: Investigation Product

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WTX-330
Description: Investigation Product

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WTX-330
Description: Investigation Product
Study: NCT06520579

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Proactive pharyngeal-laryngeal Exercise Program
Description: This program consists of daily proactive pharyngeal-laryngeal exercises and weekly sessions with a speech-language pathologist post surgery. One week prior to surgery participants will begin daily proactive pharyngeal-laryngeal exercises and continue these daily exercises for 6 weeks post surgery. Beginning approximately one week after surgery, participants will meet with the speech-language pathologist. Sessions will occur weekly, for approximately 6 weeks, and will last approximately 45 minutes.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Premier Protein Clear ® High Protein
Description: Premier Protein Clear ® High Protein (20 grams of protein and 90 calories per 16.9 oz. drink) 1 drink daily for 7 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hydration Counseling
Description: Daily hydration goals are based on recommended guidelines for adults, by gender, from The United States National Academy of Medicine (US NAM) and the European Food Safety Authority (ESFA) (\~2.0 L/day for women; \~2.5 L/day for men of fluid intake, accounting for 20% daily fluid intake from food sources). Patients will be required to track via paper log whether they met their hydration goals daily.
Study: NCT05324176

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: diaphragmatic ultrasound
Description: diaphragmatic thickness will be measured on both sides during a deep breath in inspiration and during expiration.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: diaphragmatic ultrasound
Description: diaphragmatic thickness will be measured on both sides during a deep breath in inspiration and during expiration.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: diaphragmatic ultrasound
Description: diaphragmatic thickness will be measured on both sides during a deep breath in inspiration and during expiration.
Study: NCT06163820

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab is a humanised monoclonal antibody with molecular weight 167kD that inhibits all isoforms of the vascular endothelial growth factor (VEGF) and is produced from a Chinese hamster ovary mammalian system. It has high specificity for isoform-A and has a half-life of \~21 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab is an immune checkpoint inhibitor (ICI) that targets anti-tumour immunity. Ipilimumab is a recombinant human immunoglobulin monoclonal antibody that binds CTLA4 and blocks the interaction between CD80/86 and CTLA4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab ia an immune checkpoint inhibitor (ICI) that targets anti-tumour immunity. Nivolumab is a fully human monoclonal IgG4 antibody targeting PD-1 which demonstrates activity across a range of tumours.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated stereotactic radiotherapy
Description: Hypofractionated stereotactic radiotherapy (hSRT) will be delivered to previously untreated brain metastases in eligible participants. hSRT will be delivered to all symptomatic brain metastases, all brain metastases \>1 cm and all brain metastases located in eloquent areas of the brain. hSRT will be commenced after the first cycle of nivolumab plus ipilimumab and completed before the second cycle of nivolumab plus ipilimumab. hSRT should be commenced within 1 week from the planning MRI.
Study: NCT05337930

Intervention type: DEVICE
Group type: OTHER
Intervention: Happyr App
Description: The Happyr app offers three main areas:~(A) A mood diary in which a user can keep track of emotional wellbeing by answering three short questions.~(B) A pain diary in which a user and supporter can record headache attacks by answering a set of predefined questions whenever a user experiences or has experienced a headache attack.~(C) An overview section in which entries from the mood and pain diary are visualized for the user. In this section, a PDF document can also be exported with a summary of data from the symptom diary that can be taken to the clinician.~A standardized notification is sent to each user at 6pm local time to remind them about logging their mood and symptoms of a headache attack.
Study: NCT05509946

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single dose of celecoxib 400 mg and pregabalin 150 mg
Description: Single dose of celecoxib 400 mg and pregabalin 150 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Repeated dose of celecoxib 200 mg and pregabalin 75 mg
Description: Repeated dose of celecoxib 200 mg and pregabalin 75 mg started 3 days before surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT06532513

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Family-Centered Goal-Oriented Physiotherapy and Rehabilitation Application
Description: Family centered goal-oriented physiotherapy and rehabilitation applications aim to enhance the functional level of severely affected children with dyskinetic cerebral palsy children through individualized activities conducted by family members at home. The program focuses on specific goals determined collaboratively by the family, physiotherapists, and physician, with regular monitoring and assessments to track progress.
Study: NCT06378099

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient guided and followed by the pharmacist
Description: The Study Coordinating Group will train the pharmacy Staff regarding these protocols.~The training will include both pharmacological and non-pharmacological aspects of managing MA. In the pharmacological component, emphasis will be placed on the appropriate selection of OTC medications to address different MA, with special attention to identifying potential drug interactions, contraindications, and potential ADRs. Tools will also be provided to advise patients on the correct and safe use of these medications, and the criteria for referral to a physician.~The staff will be divided into three groups, and every group will have a minimum of two sessions, each one of 4 hours. Additionally, there will be a practical component where simulations of real situations will be conducted.~Throughout the 12-month follow-up and intervention period, one of the researchers will be available to receive phone calls to address doubts and concerns about the Pharmaceutical Indication Protocol.
Study: NCT05800457

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Partial synovectomy
Description: Patients in the intervention group will undergo partial synovectomy during total knee replacement surgery
Study: NCT04472091

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Genicular artery embolization (GAE)
Description: Participants will undergo GAE with HydroPearl® Microspheres (polyethylene glycol microspheres, Terumo Medical, Somerset NJ).
Study: NCT04994535

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA
Description: Injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline injection
Study: NCT06562504

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS)- anodal group
Description: 2mA/20mins/session;

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial direct current stimulation (tDCS)- sham group
Description: 0mA/20mins/session

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial alternating current stimulation (tACS)-tACS group
Description: 1.5 mA/20 min/session; 6HZ, theta
Study: NCT06013150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epinephrine
Description: Participants in Part 1 of the study will receive single dose either 1mg, 1.3mg or 1.5mg of an inhaled single dose of Epinephrine or placebo delivered via DMC-IHI device.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Epinephrine
Description: Participants in Part 1 of the study will receive single dose either 1mg, 1.3mg or 1.5mg of an inhaled single dose of Epinephrine or placebo delivered via DMC-IHI device.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participant in Part 1 of the study will receive matching doses of placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participant in Part 1 of the study will receive matching doses of placebo
Study: NCT05577468

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tegoprazan
Description: tegoprazan-containing bismuth quadruple therapy or Esomeprazole-containing bismuth quadruple therapy; Route of administration: oral;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tegoprazan
Description: tegoprazan-containing bismuth quadruple therapy or Esomeprazole-containing bismuth quadruple therapy; Route of administration: oral;
Study: NCT06258473

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Multicomponent decentralized care
Description: 1. Training and support on Simple app for HTN/DM management \& training NCD corner clinicians on clinical guidelines and establish team-based care for Upazila level NCD corner~2. CHCPs conduct BP/BG screening, monitoring, lifestyle counseling, dispensing of medications, follow-up overdue patients at CCs \& CHCP care coordination supported by Simple app at community clinics~3. CHWs assist in screening, counselling, referral, and follow-up for CHW at village level
Study: NCT06653634

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Gradual withdrawal of the medication

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Gradual withdrawal of the medication
Study: NCT06258473

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: mHealth
Description: Training and support on Simple app for HTN/DM patient management \& training NCD corner clinicians on clinical guidelines of Upazila Health complex
Study: NCT06653634

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TNF Inhibitor
Description: Gradual withdrawal of the medication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNF Inhibitor
Description: Gradual withdrawal of the medication
Study: NCT06658119

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cataract surgery
Description: The participants will receive femtosecond laser-assisted cataract surgery and implant an extended depth-of-focus intraocular lens (Tecnis Synergy ZFR00).

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: cataract surgery
Description: The participants will receive femtosecond laser-assisted cataract surgery and implant an extended depth-of-focus intraocular lens (Tecnis Symfony ZXR00).